CEO Michael Farrell reported 10% global revenue growth, driven by demand across the sleep health, breathing health, and residential care software portfolios. Device sales, including AirSense 10 and ...

Brett Fishbin; Analyst; KeyBanc Capital Markets Inc. Welcome to the Q2 fiscal-year 2025 ResMed earnings conference call ... reflecting the continuing demand for our AirSense 10 and AirSense 11 ...

Resmed has its origins in the 1980s, when Sydney sleep expert Dr Colin Sullivan converted a vacuum cleaner to deal with the ...

Due to its significant market share and high gross margins in a structurally growing industry, ResMed has posted an average return on invested capital, or ROIC, of 20% over the last decade. We ...

ResMed has a minority stake in Nyxoah who are developing a neurostimulation implant to treat OSA. Although we see little near ...

ResMed reported a revenue increase of 10% year-over-year ... attributed to manufacturing and cost improvements. The AirSense 11 has become the majority of ResMed's global product mix, which ...

On Friday, Oppenheimer analysts maintained a Perform rating on ResMed (NYSE:RMD) following the company's financial results for the second quarter of fiscal year 2025. ResMed reported a revenue ...

It is similar in some ways to other therapy modes, including CPAP and bilevel. There are pros and cons ... Also known as APAP, auto-titrating, or by brand names such as AirSense (used by ResMed), ...